1. Home
  2. > Pharmaceutical Market Trends
China Cell Therapy Market Opportunity & Clinical Trials Insight 2028

China Cell Therapy Market Opportunity & Clinical Trials Insight 2028

  • October 2022
  • 510 pages
  • ID: 6351384
  • Format: PDF
  • Kuick Research


Table of Contents

China Cell Therapy Market Opportunity & Clinical Trials Insight 2028 Report Highlights:

• More Than 400 Cell Therapies Are In Clinical Trials In China
• 2 Cell Therapies Are Commercially Approved
• Insight on More Than 25 Cell Therapies Proprietary Technologies Developed By Chines Companies
• China Cell Therapy Market Opportunity Assessment
• Insight On More Than 400 Cell Therapies In Clinical Trials By Phase, Indication, Company
• Analysis On Pricing & Reimbursement Framework
• Insight On Key Chinese Pharmaceutical Companies Involved In R&D OF Cell Therapies

China has emerged as one of the world’s largest pharmaceutical markets as a result of a exponential rise in clinical research and development activity in recent years. It has additionally evolved into one of the most popular destinations for holding clinical trials, with R&D activity encompassing a variety of therapeutic fields and diseases. Chinese pharmaceutical companies have moved their focus from manufacturing generic drugs to developing innovative drugs and therapies after learning from their international counterparts. The recent advancement in the treatment of cancer, particularly with the introduction of immunotherapy to the international research landscape, was one of the most recent changes in China’s pharmaceutical industry.

Immunotherapy has become one of the most sought after oncology treatments in recent years. China entered this industry slowly, but ever since it did, it has made enormous strides. CAR T Cell therapy is one of the most popular immunotherapies in China. Hundreds of CAR T Cell therapy candidates are currently undergoing clinical trials for the treatment of different diseases worldwide, around 20%-30% of which are being conducted in China, demonstrating the country’s growing stature in the pharmaceutical industry. A large number of these clinical trials are being carried out against different forms of cancer, it being the leading cause of death in China and CAR-T cells have emerged as the front runner as the most used cells in the trials. Other immune cells like TIL and TCR have been tested in a fair share of clinical trials but their effectivity has been unsatisfactory which directed the attention of researchers in China towards the development CAR-T cells, which are genetically engineered human T lymphocytes.

The collection and incubation of CAR-T cells is a time taking process, wherein extra care has to be taken to prevent contamination. To help make this process simpler, many companies have developed proprietary technology platforms to encounter the various obstacles faced in the development process. For instance FasTCAR, developed by Gracell Bio, reduces the manufacturing time, improved the quality of the T-cells, among other additional benefits. There are many other platforms which have been constructed in recent times for the same purpose and have been the highlight of several partnerships in China’s cell therapy market.

FKC876 and Carteyva, the two CAR-T therapies that have been approved in China, are the products of two joint ventures that came into being, allowing the access of proprietary platforms of Kite Pharma and Juno Therapeutics to their Chinese partners, who then developed the drugs in mainland China. Neither of these two drugs is currently available in the market, nor have the companies revealed any plans of doing so, at least in the near future. Not only large pharma companies but even some CROs and CDMOs in China, like BioHeng, own innovative platforms that substantially reduce the manual effort and time which is invested in the maturation of these cells to be used in the treatment of severe diseases.

The major focus of researchers globally has been on the development autologous cell therapies; however they have now slowly directing their attention towards the development of allogeneic the cell therapies. These provide the same effects as autologous therapies but can be stored by hospitals, allowing a ready-for-use and quick treatment option. This trend has also seeped into the Chinese R&D sector, with clinical trials underway for different hematological malignancies.

The regulatory and policy framework has played the biggest role in this changing market dynamics in china. Historically being known for its slow integration towards western companies, its policies have since then evolved and have become more welcoming, urging the entry of more international companies in its pharma industry. This has not only given a boost to its pharma market but has also supported the growth of its domestic pharma companies by allowing the exchange of knowledge and proprietary technologies among companies in return for commercializing drugs developed by these western companies, in China and surrounding regions.

China’s pharma market has been growing rapidly over the last couple of years because of the interplay of several factors. As science and technology evolve and enter China, its cell therapy market, which is already constantly expanding to other indications, is expected to get a boost and will give the US strong competition in the future.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Biologics Contract Development Market Research Report by Source, Type, Disease Indication, Product Service, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

  • $ 3949
  • January 2023
  • 237 pages

Biologics Contract Development Market Research Report by Source (Mammalian and Microbial), Type, Disease Indication, Product Service, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and ...

  • World
  • Cell Therapy
  • Marketing Research
  • Industry analysis


Reportlinker.com © Copyright 2023. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on